U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07034859) titled 'Cabergoline in the Management of Nonfunctioning Pituitary Adenoma' on June 04.
Brief Summary: The goal of this clinical trial is to learn if Cabergoline (Dostinex), a dopamine agonist which has been widely used to treat hyperprolactinemia, prolactinoma for many years, works to treat nonfunctioning pituitary adenoma (NFPA) in adults. The main questions it aims to answer are:
Does cabergoline reduce the size of NFPA effectively when used as primary therapy?
Participants will:
Be 1:1 randomized into two groups. Either to take cabergoline or none for 48 weeks, Visit the clinic every 12 weeks for checkups and tests, Undergo scheduled ...